rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CAMP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted no

      Nov 17Yahoo FinanceCAMP
      CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data
      Nov 11Yahoo FinanceCAMP
      CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
      Nov 10Yahoo FinanceCAMP
      CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
      Nov 6Yahoo FinanceCAMP
      CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
      Oct 29Yahoo FinanceCAMP
      CAMP4 receives EU approval for CMP-002 SYNGAP1 disorder trial
      Oct 27Investing.comCAMP
      CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
      Oct 27Yahoo FinanceCAMP
      CAMP4 Therapeutics Rings the Closing Bell

      About This EventCAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Josh Mandel-Brehm, President & Chief Executive Officer rings the Closing Bell.

      Oct 26NasdaqCAMP
      Raymond James initiates CAMP4 Therapeutics stock with strong buy rating
      Oct 23Investing.comCAMP
      Raymond James Initiates Coverage on CAMP4 Therapeutics With Strong Buy Rating, $10 PT
      Oct 23Yahoo FinanceCAMP
      CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
      Oct 20Yahoo FinanceCAMPKRRO
      Needham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price Target
      Oct 15Yahoo FinanceCAMP
      CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
      Oct 14Yahoo FinanceCAMP
      Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target
      Oct 5Yahoo FinanceCAMP
      Cantor Fitzgerald reiterates Overweight on CAMP4 stock at $7 target
      Sep 29Investing.comCAMP
      Chardan Trims Price Target on CAMP4 Therapeutics to $6 From $6.50, Keeps Buy Rating

      CAMP4 Therapeutics (CAMP) has an average rating of buy and mean price target of $9.43, according to

      Sep 29Yahoo FinanceCAMP
      Camp4 Therapeutics Corporation (CAMP) Analyst/Investor Day - Slideshow (NASDAQ:CAMP) 2026-09-28
      Sep 28Seeking AlphaCAMP
      CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002

      CAMP4 Therapeutics (NASDAQ:CAMP) said it expects to dose the first patient in its Phase I/II ASCEND trial of CMP-002 for SYNGAP1-related disorder during the fourth quarter, with top-line results targeted for the first half of 2028. The company’s analyst event focused on CMP-002, an antisense oligon

      Sep 28Yahoo FinanceCAMP
      CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002
      Sep 10Investing.comCAMP
      CAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UK
      Sep 10Yahoo FinanceCAMP
      CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

      Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company anticipates initiation of the clinical trial in 4Q 2026 WATERTOWN, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics design

      Sep 10Yahoo FinanceCAMP
      Camp4 Therapeutics at Cantor conference: pushing first SYNGAP1 trial
      Sep 9Investing.comCAMP
      CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

      WATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will host a virtual Analyst Day on Monday, September 28, 2026 from 12:00 – 1:30 PM ET featuring presentations and Q&A led by CAMP4’s executive leadersh

      Sep 8Yahoo FinanceCAMP
      Camp4 CFO Kelly Gold buys $39,600 in company stock
      Sep 3Investing.comCAMP
      CAMP4 to Participate in Upcoming Investor Conferences

      WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare C

      Sep 1Yahoo FinanceCAMP
      Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock
      Sep 1Investing.comCAMP
      Camp4 Therapeutics director Andrew Schwab sells $45 in shares
      Aug 27Investing.comCAMPSCHW
      Camp4 Therapeutics Insider Sold Shares Worth $879,719, According to a Recent SEC Filing

      Andrew J. Schwab, Director, on August 19, 2026, sold 191,865 shares in Camp4 Therapeutics (CAMP) for

      Aug 21Yahoo FinanceCAMP

      This is the newest page. Registered accounts read further back.